3. Categories

      eCliniqua: eClinical Products, Electronic Data Capture (EDC), Market Insights, Regulatory Issues & Drug Safety, Trial Design and Logistics

  6. SPONSORED LINKS

    Optimize Trial Design through Simulation Modeling - Webinar

    White Paper: Improving Drug Manufacturing Quality with a SDMS

    Exemplar Biomarker Discovery – Your Complete Solution for Personalized Medicine

    Free Webinar - Running Adaptive Clinical Trials: Myth and Reality

    Free Webinar on Compliance and Patient Data –Meeting the Needs!

    Grid Engine @ Univa: 200 improvements and counting

    Analyze, compare & visualize NGS datasets with CLC bio's intuitive platform

    Protect Your Kingdom - RSA Conf 2012

    Free whitepaper: Understanding Legal Issues Surrounding Electronic Lab Notebook Records

    ClearTrial Named a Gartner "Cool Vendor in Life Sciences, 2011"

    Data Repository, ELN, & Laboratory Execution - Waters® NuGenesis® SDMS

    Discover Timaeus 5, an on-demand eClinical platform for Study Design Through Reporting.

    Free WhitePaper: Increase Innovation with Improved Scientific Data Management

    Biotech 2010 Life Sciences: Adapting for Success

    Online community for pioneers in next-gen sequencing & bioinformatics

    Barnett International: Training Strategy and Consulting

    Competitive Analysis & Insight with Concise Research Reports

    Current & Innovative NGS Technologies, Services & Markets

    Next Generation Mass Spectrometry

    New Trends in Preventive and Therapeutic Vaccines

    Next-Generation Sequencing Technologies: Applications and Markets

  1. Amylin Pharmaceuticals

    0 Comments Leave a Comment

    1-5 of 5

    1. Mentioned In 5 Articles

    2. Lilly, Amylin Scrap Diabetes-Drug Partnership

      Explore WSJ Blogs (Nov 11 2011) Market Insights

      Eli Lilly and Amylin Pharmaceuticals yesterday said they’d scrapped their diabetes-drug partnership, with Amylin paying $250 million to ... (Read Full Article)

      Comment Mentions:   American Medical Association   Amylin Pharmaceuticals   Eli Lilly and Company

    3. 3 Biotechs Ready to Move

      Explore Fool.com (Aug 31 2011) Electronic Data Capture (EDC) , Regulatory Issues & Drug Safety , Trial Design and Logistics

      ...t cap under $300 million, there are very little sales baked into the price. Third time's the charm? Amylin Pharmaceuticals ( ) and its partners Eli Lilly ( ) and Alkermes ( ) are headed in front of the FDA for a third atte... (Read Full Article)

      Comment Mentions:   FDA   Novo Nordisk A/S   Amylin Pharmaceuticals

    4. Running the Correct Trial Isn't Enough

      Explore Fool.com (Aug 18 2011) Electronic Data Capture (EDC) , Market Insights , Regulatory Issues & Drug Safety , Trial Design and Logistics

      ...hat's great; you can't gain FDA approval without running the right trial. Just as Eli Lilly ( ) and Amylin Pharmaceuticals ( ) , which had to run a heart trial that the FDA decided was needed for Bydureon. Or MannKind ( ) ... (Read Full Article)

      Comment Mentions:   FDA   Amylin Pharmaceuticals   Eli Lilly and Company

    5. Amylin sues Lilly over diabetes partnership

      Explore reuters.com (May 16 2011) Market Insights

      Amylin Pharmaceuticals Inc sued longtime diabetes-drug partner Eli Lilly & Co over its plans to help market a rival produc... (Read Full Article)

      Comment Mentions:   Amylin Pharmaceuticals   Eli Lilly and Company   Amylin

    6. There Are No Safe Biotech Investments

      Explore Fool.com (Oct 21 2010) Regulatory Issues & Drug Safety , Trial Design and Logistics

      Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Admini... (Read Full Article)

      Comment Mentions:   FDA   GlaxkSmithKline plc   Novo Nordisk A/S

    7. 1-5 of 5